Concepedia

Author

Rod Humerickhouse

AbbVie (United States)

Also Known As

R A Humerickhouse, R Humerickhouse, R. A. Humerickhouse, R. Humerickhouse, R.A. Humerickhouse, Rod A Humerickhouse, Rod A. Humerickhouse, Rod Humerickhouse

136

Publications

18.3K

Citations

44

H-Index

69

Concepts

All Affiliations

AbbVie (United States)Dana-Farber Cancer InstituteThe University of Texas MD Anderson Cancer CenterPeter MacCallum Cancer CentreUniversity of California San Diego
RH

About

Rod Humerickhouse is an author at AbbVie (United States) specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

34

8.3K

2

Health Sciences

13

14

5K

3

Biochemistry

6

6

513

4

Natural Sciences

4

4

477

5

Engineering

1

1

21

Rod Humerickhouse

×

87

Publications

18K

Citations

43

H-Index

YearCitations

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler,

Nature Medicine

2013

2.9K

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel,

New England Journal of Medicine

2015

1.8K

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri,

Cancer Discovery

2016

1K

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst,

New England Journal of Medicine

2018

881

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman,

The Lancet Oncology

2010

840

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo,

New England Journal of Medicine

2019

816

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown,

Journal of Clinical Oncology

2011

808

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig,

The Lancet Oncology

2016

783

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour,

Journal of Clinical Oncology

2017

737

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Courtney D. DiNardo, Keith W. Pratz, Anthony Letai,

The Lancet Oncology

2018

692

Page 1